BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.
About IsoPlexis
IsoPlexis is the Superhuman Cell company.
By leading the discovery and identification of how multi-functional immune— Superhuman— cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.
IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and at over 70% of leading U.S. comprehensive cancer centers.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in…
LOS ANGELES, May 5, 2025 /PRNewswire/ -- SprintRay, the global leader in dental 3D printing,…
Oakville, Ontario--(Newsfile Corp. - May 5, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…
DANA POINT, Calif.--(BUSINESS WIRE)--The Lens, LSI’s executive-focused medtech magazine, proudly unveils Volume 2, Edition 3,…
PUNE, India, May 5, 2025 /PRNewswire/ -- The global Digital Wound Management Devices Market was…
Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity management MIAMI, May 5, 2025 /PRNewswire/ -- eMed®,…